MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why AVIR Stock advanced +0.94% Today — RQD Quant Desk Flash
$4.31 +0.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.31
Atea Pharmaceuticals Inc. (AVIR) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $345.7M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.31 (-0.02%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVIR)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY AVIR SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)
FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 32.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$5.15-16.1% Next Q
48
Q2 (-2Q)Grade D$4.32-6.5% Next Q
45
Q3 (-1Q)Grade D$4.04+6.7% Next Q
43
CurrentGrade D-$4.31-7.4% Hist 90D α
40
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AVIR Turnaround Squeeze
While AVIR currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.04) and Max Pain ($4.53) forces dealer call-delta covering toward $6.77.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVIR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AVIR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AVIR Stock advanced +0.94% Today — RQD Quant Desk Flash
Atea Pharmaceuticals Inc. (AVIR) advanced +0.94% to $4.31, trading at 40% of its 52-week range ($2.87 – $6.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 40% of its 52-week range ($2.87 – $6.45) with RSI-14 at 32.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.6% around $4.31 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AVIR Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVIR)
- ✓Walkthrough of AVIR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AVIR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.78%▲ ASCENDING CHANNEL
2026-10-30O $4.30H $4.32L $4.07C $4.31VOL 349.9K
RES: $6.54SUP: $3.94SMA50: $5.04SMA200: $4.93
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AVIR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AVIR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AVIR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AVIR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVIR)
Health Care Rank #640 of 1016
⚔️ ARCT vs AVIR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AVIR vs. ARCT, CTNM, GALT, CYPH)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Atea Pharmaceuticals Inc. (AVIR) ranks #640 by composite RQD confidence (40/100, grade D-) and #502 by equity capitalization ($345.7M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. GALT currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with AVIR at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AVIR
ACTIVE
Atea Pharmaceuticals Inc. | D- | 40/100 | — | — | -35.0% | +0.94% | $345.7M | Benchmark Subject |
| ARCT Arcturus Therapeutics Holdings Inc. | E | 31/100 | — | — | -35.0% | +0.66% | $345.3M | /arct-vs-avir → |
| CTNM Contineum Therapeutics Inc. (Class A) | D- | 40/100 | — | — | -29.0% | +1.97% | $351.0M | /ctnm-vs-avir → |
| GALT Galectin Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -0.56% | $355.8M | /galt-vs-avir → |
| CYPH Cypherpunk Technologies Inc. | D- | 40/100 | 71.3x | — | -23.3% | +2.16% | $356.7M | /cyph-vs-avir → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001593899In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atea Pharmaceuticals Inc. (AVIR) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$158.0M, operating cash flow of -$132.0M, and free cash flow of -$132.0M (+2.6% YoY). On the balance sheet, AVIR closed FY2025 with $315.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$158.0M | -$132.0M | -$132.0M | $315.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$168.0M | -$135.5M | -$135.5M | $464.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$136.0M | -$85.4M | -$85.4M | — | — |
3. AVIR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AVIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Atea Pharmaceuticals Inc. (NASDAQ: AVIR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $4.31 (+0.94% 1D, market cap $345.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AVIR ranks #640 in composite RQD confidence.
How does AVIR compare to ARCT and CTNM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AVIR carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ARCT (Arcturus Therapeutics Holdings Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $345.3M) and CTNM (Contineum Therapeutics Inc. (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -29.0%, cap $351.0M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AVIR?
Per AVIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001593899), Atea Pharmaceuticals Inc. generated $0 in revenue, -$158.0M in net income, and -$132.0M in free cash flow against $315.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AVIR trading relative to its 50-day, 200-day, and 52-week technical levels?
AVIR last traded at $4.31 (+0.94% on volume of 280,876 shares), positioning the stock -14.48% below its 50-day simple moving average ($5.04) and -12.58% below its 200-day simple moving average ($4.93). Across its 52-week range of $2.87 to $6.45, AVIR sits at the 40.2% percentile with a 14-day RSI of 32.4 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($3.81 to $4.81).
AVIR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AVIR stock moving today?
Why AVIR Stock advanced +0.94% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.